Caprylidene (trade name Axona) is a medical food that was approved in March 2009 by the U.S. Food and Drug Administration for the "clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease". Glucose metabolism by the brain is impaired in Alzheimer's disease, and it is proposed that ketone bodies may provide an alternative energy source. Caprylidene is a powdered form of caprylic triglyceride, a medium chain triglyceride (MCT) in which three molecules of caprylic acid are esterified with glycerol.
- Accera. (February 2011). Axona Description (Prescribing Information). Retrieved April 26, 2011 from www.about-axona.com.
- Henderson ST. (July 2008). Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 5 (3): 470-480.